Talazoparib plus enzalutamide in high-volume metastatic hormone-naive prostate cancer: a randomized phase 2 trial
Nature Medicine, Published online: 14 October 2026; doi:10.1038/s41591-026-04671-5 In the randomized multicenter phase 2 ZZ-FIRST trial, patients with high-volume metastatic hormone-sensitive prostate cancer treated with poly(ADP-ribose) polymerase inhibitor talazoparib combined with androgen receptor inhibitor enzalutamide had an improved prostate-specific antigen response compared with…
We haven't written up this one. Nature Medicine has the full story — the link below goes straight to it.
